Evaluating the potential mediating role of ADAMTS13 activity in the relationship between obesity and the severity of COVID-19: A retrospective cohort study
Authors:
- Wael HafezWael Hafez
- Hesham Mohamed AbuelsaoudHAHesham Mohamed Abuelsaoud
- Mohan JoseMJMohan Jose
- Samy KishkSKSamy Kishk
- Muneir Mrcp GadorMGMuneir Mrcp Gador
- Tesfalidet Mbbch EmosheTETesfalidet Mbbch Emoshe
- Fatema Mbbch AbdulaalFAFatema Mbbch Abdulaal
- Nivedita Mbbch NairNNNivedita Mbbch Nair
- Muhammad Mbbch AhmadMAMuhammad Mbbch Ahmad
- Vanya Jalal Mbbch RashidVRVanya Jalal Mbbch Rashid
- Youmna Mbbch FaheemYFYoumna Mbbch Faheem
Open Access
- 12 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (15) , e37806
Abstract
Obesity and low enzyme A disintegrin and metalloproteinase with thrombospondin type-1 motif-13 (ADAMTS13) activity have been linked to poor coronavirus disease 2019 (COVID-19). Given that obesity may influence ADAMTS13 activity, it is feasible; however, it remains unclear whether ADAMTS13 activity acts as a mediator between obesity and COVID-19 outcomes. We investigated the link between body mass index (BMI) and COVID-19 outcomes, using ADAMTS13 activity as a mediator. ADAMTS13 activity was measured in 86 hospitalized COVID-19 patients. BMI, ADAMTS13 activity, and COVID-19 outcomes were assessed. Obese patients had a high odds ratio for low ADAMTS13 levels. When different levels of ADAMTS13 activity were considered, the severity of COVID-19 in obese patients was 4.5 times that in the normal BMI group. Furthermore, increased coagulopathy indicators correlated with low ADAMTS13 activity. Patients with elevated ALT and AST levels showed a 3 to 4-fold increase in the chances of low ADAMTS13 activity (OR:3.19, 95% CI:1.22–8.90, P = .021; OR:2.17, 95% CI:0.91–5.27, P = .082, respectively). When ADAMTS13 activity was considered, obese patients had greater COVID-19 severity and slower viral clearance than those with normal BMI. Low ADAMTS13 activity and impaired liver function are associated with poor COVID-19 outcomes. These findings encourage researchers to use molecular component identification to study the effects of obesity on the von Willebrand factor (VWF)/ADAMTS13 axis, COVID-19 pathogenesis, and outcomes.Keywords
This publication has 41 references indexed in Scilit:
- Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in EgyptInfection, 2022
- Reduced ADAMTS13 Activity in Correlation with Pathophysiology, Severity, and Outcome of COVID-19: A Retrospective Observational StudyInternational Journal of Infectious Diseases, 2022
- Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus‐2 infectionJournal of Clinical Laboratory Analysis, 2021
- COVID-19-associated coagulopathy and disseminated intravascular coagulationInternational Journal of Hematology, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical VentilationObesity, 2020
- COVID-19 update: Covid-19-associated coagulopathyJournal of Thrombosis and Thrombolysis, 2020
- Elevated ADAMTS13 Activity is Associated with Poor Postoperative Outcome in Patients Undergoing Liver ResectionScientific Reports, 2018
- An Unbalance Between von Willebrand Factor and ADAMTS13 in Acute Liver Failure: Implications for Hemostasis and Clinical OutcomeHepatology, 2013
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982